Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.83
-0.0600-3.17%
Post-market: 1.840.0100+0.55%19:55 EDT
Volume:890.93K
Turnover:1.61M
Market Cap:77.30M
PE:-2.87
High:1.94
Open:1.90
Low:1.75
Close:1.89
52wk High:4.34
52wk Low:1.41
Shares:42.24M
Float Shares:40.90M
Volume Ratio:1.46
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6370
EPS(LYR):-0.8920
ROE:-155.66%
ROA:-66.93%
PB:4.16
PE(LYR):-2.05

Loading ...

Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Dec 19, 2025

Gain Therapeutics Hosts Virtual KOL Event Showcasing GT-02287 Biomarker Data for Parkinson’s Disease

Reuters
·
Dec 19, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:30 AM

Reuters
·
Dec 18, 2025

Gain Therapeutics Reports First Reduction of GluSph in Parkinson’s Patients with GT-02287 in Phase 1b Trial

Reuters
·
Dec 18, 2025

Gain Therapeutics Inc - Shows Reduction in Gcase Substrate for Pd

THOMSON REUTERS
·
Dec 18, 2025

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint From Its Phase 1B Clinical Study of GT-02287 in People With Parkinson’s Disease

THOMSON REUTERS
·
Dec 18, 2025

LIVE MARKETS-Stocks gain, yields little changed after Fed's hawkish cut

Reuters
·
Dec 11, 2025

Gain Therapeutics Announces New Stock Offering Program

TIPRANKS
·
Nov 29, 2025

BRIEF-Gain Therapeutics Files Prospectus For $35.5 Million Stock Sale - SEC Filing

Reuters
·
Nov 29, 2025

Gain Therapeutics Inc - Files Prospectus for $35.5 Mln Stock Sale - SEC Filing

THOMSON REUTERS
·
Nov 29, 2025

Gain Therapeutics Unveils Preclinical Data Showing GT-02287 Boosts Mitochondrial Function in Parkinson’s Models

Reuters
·
Nov 20, 2025

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

GlobeNewswire
·
Nov 20, 2025

Positive Outlook for Gain Therapeutics: Promising Clinical Trial Results and Stable Financial Health Drive Buy Rating

TIPRANKS
·
Nov 16, 2025

Gain Therapeutics Reports Continued Progress Amid Financial Challenges

TIPRANKS
·
Nov 13, 2025

Gain Therapeutics Q3 EPS $(0.15) Beats $(0.16) Estimate

Benzinga
·
Nov 12, 2025

Gain Therapeutics Q3 EPS USD -0.15

THOMSON REUTERS
·
Nov 12, 2025

Gain Therapeutics Completes Phase 1b Enrollment and Reports Q3 2025 Results

Reuters
·
Nov 12, 2025

Press Release: Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Dow Jones
·
Nov 12, 2025

Gain Therapeutics Unveils GT-02287 Parkinson’s Therapy Data at Neuroscience 2025

Reuters
·
Oct 30, 2025

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

GlobeNewswire
·
Oct 16, 2025